HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

A Comparison of the effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters : A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)

フルテキスト
biomedfrontiers_miyoshi.pdf217.16 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/68417

タイトル: A Comparison of the effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters : A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)
著者: Nomoto, H 著作を一覧する
Miyoshi, H 著作を一覧する
Furumoto, T 著作を一覧する
Oba, K 著作を一覧する
Tsutsui, H 著作を一覧する
Miyoshi, A 著作を一覧する
Kondo, T 著作を一覧する
Tsuchida, K 著作を一覧する
Atsumi, T 著作を一覧する
Manda, N 著作を一覧する
Kurihara, Y 著作を一覧する
Aoki, S 著作を一覧する
SAIS Study Group 著作を一覧する
発行日: 2016年 4月
出版者: World Biomedical Frontiers
引用: World Biomedical Frontiers
抄録: Objective: Glucagon-like peptide-1 (GLP-1) improves hyperglycemia, and it has been reported to have favorable effects on atherosclerosis. However, it has not been fully elucidated whether GLP-1 is able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of the GLP-1 analogue, liraglutide on endothelial function and glycemic metabolism compared with insulin glargine therapy. Materials and Methods: In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8 %) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks. Flow mediated dilatation (FMD), a comprehensive panel of hemodynamic parameters (Task Force Monitor), and serum metabolic markers were assessed before and after the treatment period. Results: A greater reduction (worsening) in %FMD was observed in the glargine group, although this change was not statistically different from the liraglutide group (liraglutide; 5.7 to 5.4 %, glargine 6.7 to 5.7 %). The augmentation index, C-peptide index, derivatives of reactive oxygen metabolites and BMI were significantly improved in the liraglutide group. Central systolic blood pressure and NT-proBNP also tended to be improved in the liraglutide-treated group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different. Conclusions: Regardless of glycemic improvement, early liraglutide therapy did not affect endothelial function but may provide favorable effects on beta-cell function and cardioprotection in type 2 diabetics without advanced atherosclerosis.
Relation (URI): http://biomedfrontiers.org/diabetes-obesity-2016-16/
資料タイプ: article
URI: http://hdl.handle.net/2115/68417
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 三好 秀明

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学